新泽西州普林斯顿 - 血液净化技术领域的领导者CytoSorbents Corporation（纳斯达克股票代码：CTSO）目前股价为$0.92，市值5000万美元，该公司宣布开始面向合格股东和特定认股权证持有人进行供股。根据InvestingPro的数据，该公司股票在过去一年下跌了48%，使得此次供股 ...

Equities research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the ...

PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

On December 9, 2024, CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin ...

CytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results. The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M ...

This was corrected on 01/05/2025 at 1:03 AM. The revised post deletes Q4 and FY24 product revenue consensus ...

CytoSorbents (CTSO) (ISIN: US23283X2062)股票专题，提供今日CytoSorbents(CTSO) (ISIN: US23283X2062)股票最新股价查询，实时市场行情，走势图表，及CytoSorbents Corp.(CTSO) (ISIN: US23283X2062)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL ...